CytomX Therapeutics to Participate at Upcoming Healthcare Conferences
28 Mayo 2020 - 3:05PM
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage
oncology-focused biopharmaceutical company pioneering a novel class
of investigational antibody therapeutics based on our Probody®
therapeutic technology platform, announced today that Sean
McCarthy, D.Phil., president, chief executive officer and chairman,
will participate in the following virtual healthcare conferences in
June.
Jefferies Virtual Healthcare Conference
Dr. McCarthy will present a Corporate Update
Date: Wednesday, June 3, 2020 Time:
11:30 a.m. ET
Goldman Sachs 41st Annual Global Healthcare Conference
Webcast
Dr. McCarthy will participate in a Fireside Chat Date:
Wednesday, June 10, 2020 Time:
4:40 p.m. ET
A live audio webcast of the presentation and fireside chat will
be available through the Events and Presentations page of CytomX's
website at www.CytomX.com. An archived replay will be available for
90 days following the event.
About CytomX Therapeutics CytomX is a
clinical-stage, oncology-focused biopharmaceutical company with a
vision of transforming lives with safer, more effective therapies.
We are developing a novel class of investigational antibody
therapeutics, based on our Probody® technology platform, for
the treatment of cancer. Probody therapeutics are designed to
remain inactive until they are activated by proteases in the tumor
microenvironment. As a result, Probody therapeutics are intended to
bind selectively to tumors and decrease binding to healthy tissue,
to minimize toxicity and potentially create safer, more effective
therapies. As leaders in the field, our innovative technology is
designed to turn previously undruggable targets into druggable
targets and to enable more effective combination therapies. CytomX
and its partners, comprised of leading biotechnology and
pharmaceutical companies, have developed a robust pipeline of
potential first-in-class therapeutic candidates against novel,
difficult to drug targets and potential best-in-class
immunotherapeutic candidates against clinically validated targets.
The CytomX clinical stage pipeline includes first-in-class product
candidates against previously undruggable targets, including a
CD166-targeting Probody drug conjugate wholly owned by CytomX
(CX-2009) and a CD71-targeting Probody drug conjugate partnered
with AbbVie (CX-2029). CD166 and CD71 are among cancer targets that
are considered to be inaccessible to conventional antibody drug
conjugates due to their presence on many healthy tissues. The
CytomX clinical stage pipeline also includes cancer
immunotherapeutic candidates against validated targets such as the
CTLA-4-targeting Probody therapeutics, BMS-986249 and BMS-986288,
partnered with Bristol Myers Squibb. CytomX has strategic drug
discovery and development collaborations with AbbVie, Amgen,
Astellas and Bristol Myers Squibb. For additional information
about CytomX Therapeutics,
visit www.cytomx.com and follow us
on LinkedIn and Twitter.
CytomX Therapeutics Forward-Looking Statements
This press release includes forward-looking statements. Such
forward-looking statements involve known and unknown risks,
uncertainties and other important factors that are difficult to
predict, may be beyond our control, and may cause the actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied in such statements. Accordingly, you should not rely on any
of these forward-looking statements, including those relating to
the potential benefits, safety and efficacy or progress of CytomX’s
or any of its collaborative partners’ product candidates, the
potential benefits or applications of CytomX’s Probody platform
technology, and CytomX’s ability to develop and advance product
candidates into and successfully complete clinical trials. Risks
and uncertainties that contribute to the uncertain nature of the
forward-looking statements include: the unproven nature of CytomX’s
novel Probody Platform technology; CytomX’s clinical trial product
candidates are in the initial stages of clinical development and
its other product candidates are currently in preclinical
development, and the process by which preclinical and clinical
development could potentially lead to an approved product is long
and subject to significant risks and uncertainties.
Additional applicable risks and uncertainties include those
relating to our preclinical research and development, clinical
development, and other risks identified under the heading "Risk
Factors" included in CytomX’s Quarterly Report on Form 10-Q filed
with the SEC on May 7, 2020. The forward-looking
statements contained in this press release are based on information
currently available to CytomX and speak only as of the date on
which they are made. CytomX does not undertake and specifically
disclaims any obligation to update any forward-looking statements,
whether as a result of any new information, future events, changed
circumstances or otherwise. Probody is a U.S. registered
trademark of CytomX Therapeutics, Inc.
Investor and Media Contact: Christopher Keenan VP, Investor
Relations and Corporate Communications
ckeenan@cytomx.com 650-383-0823
CytomX Therapeutics (NASDAQ:CTMX)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
CytomX Therapeutics (NASDAQ:CTMX)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024